[HTML][HTML] Tutorial in oral antithrombotic therapy: biology and dental implications

HR Fakhri, SJ Janket, EA Jackson… - … oral, patologia oral y …, 2013 - ncbi.nlm.nih.gov
Objectives: Recent developments of new direct oral anticoagulants that target specific
clotting factors necessitate understanding of coagulation biology. The objective of this …

[HTML][HTML] Intravenous thrombolysis in a patient using factor Xa inhibitor

D Korya, H Dababneh, M Moussavi… - Journal of Vascular …, 2014 - ncbi.nlm.nih.gov
Until recently, only warfarin was approved for the prevention of stroke in patients with AF.
Patients on warfarin with ischemic stroke were considered candidates for IV tPA as long as …

[HTML][HTML] Is intravenous recombinant tissue plasminogen activator (r-tPA) safe in patients on Dabigatran?

R Govindarajan, N Galvez - Journal of Vascular and Interventional …, 2014 - ncbi.nlm.nih.gov
Is intravenous recombinant tissue plasminogen activator (r-tPA) safe in patients on Dabigatran?
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Dabigatran etexilate: management in acute ischemic stroke

PP Javedani, BZ Horowitz, WM Clark… - American Journal of Critical …, 2013 - AACN
A 54-year-old man treated with dabigatran experienced new onset of a stroke with a score of
9 on the National Institutes of Health Stroke Scale. Administration of recombinant tissue …

[HTML][HTML] Endovascular treatment in acute ischemic stroke patient on factor Xa inhibitor

S Mehta, H Dababneh, M Hussain… - Journal of Vascular …, 2014 - ncbi.nlm.nih.gov
Background Warfarin has primarily been used for prevention of ischemic stroke in patients
with atrial fibrillation for nearly 30 years [1]. More recent studies and trials have …